Literature DB >> 2580618

Chromatin-associated protein kinases in human normal and benign hyperplastic prostate.

A Rayan, S A Goueli, P Lange, K Ahmed.   

Abstract

Nuclear phosphoproteins and protein kinases of human normal and benign hyperplastic prostate (BPH) were studied in an effort to delineate their properties and to identify any underlying differences therein. Chromatin-associated protein kinases active towards phosvitin, lysine-rich histone, and endogenous nonhistone proteins were characterized in human prostatic nuclei. The general properties of the human chromatin-associated prostatic protein kinases were similar to those of rat ventral prostate chromatin. Polyamines stimulated the phosphorylation of endogenous nonhistone proteins and phosvitin. Protein kinases active towards phosvitin and lysine-rich histones were unaltered in chromatin from BPH tissue as compared with the normal prostate. However, phosphorylation of chromatin-associated nonhistone proteins was markedly enhanced (average, 123%) in BPH tissue as compared with the normal tissue. The results indicate a change in the protein kinase reaction specifically involving chromatin-associated nonhistone proteins of BPH tissue as compared with normal human prostate.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580618

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.

Authors:  Janeen H Trembley; Gretchen M Unger; Diane K Tobolt; Vicci L Korman; Guixia Wang; Kashif A Ahmad; Joel W Slaton; Betsy T Kren; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2011-07-15       Impact factor: 3.396

Review 2.  CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer.

Authors:  Janeen H Trembley; Betsy T Kren; Md Joynal Abedin; Rachel I Vogel; Claire M Cannon; Gretchen M Unger; Khalil Ahmed
Journal:  Pharmaceuticals (Basel)       Date:  2017-02-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.